In the set of laboratory markers, triglyceride, AST, and ALT levels were meaningfully more in NAFLD-positives than NAFLD-negatives (P < 0.05) (Table 1). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.